Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT: NCT03257033 · RECRUITING

NCT IDNCT03257033
StatusRECRUITING
Start Date2018-03-12
Completion2027-09
SponsorRenovoRx (INDUSTRY)
First posted
Last updated

Brief Summary

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Frequently Asked Questions

What is Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC?

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC is a clinical trial registered under NCT03257033. Current status: RECRUITING.

What is the status of NCT03257033?

The current status of NCT03257033 (Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC) is: RECRUITING.

When did Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC start?

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC started on 2018-03-12.

Related Devices

K160067RenovoCathRenovorx, Inc. K191606RenovoCathRenovorx, Inc. K212324RenovoCathRenovorx, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑